The Quantellect read.As of Nov 19, 2026, 3 active firms cover Cognition Therapeutics Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 563% above the current $0.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $-0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.00
+563.2% upside
Average target across 1 active firms as of Nov 19, 2026 vs $0.60 current
Highest Target$4.00
Average Target$4.00
Lowest Target$4.00
Detailed analyst forecasts for CGTX
Showing 1–1 of 1 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate CGTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CGTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.04 · 1 analysts · -20% YoY
Next period, 1 analysts expect Cognition Therapeutics Inc to earn $-0.04 a share (range $-0.04 – $-0.04), versus $-0.05 a year earlier. Full-year consensus is $-0.18, growing to $-0.18 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Cognition Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CGTX.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$4.00+563.2% to target
Overall win rate
52%
+ Follow
#2
WW
William Wood
B. Riley Securities
Buy
$3.00+397.4% to target
Coverage
—
+ Follow
CGTX stock forecast FAQ
What is CGTX's average 12-month price target?+
The 1 active firms with a live target average $4.00 for Cognition Therapeutics Inc over the next 12 months, ranging from a $4.00 high to a $4.00 low, as of Nov 19, 2026.
Is CGTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CGTX?+
3 active firms have a recognized rating on Cognition Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CGTX?+
Among analysts who currently cover CGTX, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $4.00 target.
What is Cognition Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.04) across 1 analysts. Full-year EPS is projected at $-0.18, rising to $-0.18 the following year.
How much revenue is Cognition Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CGTX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate CGTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CGTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.